Effects of Glucagon-Like Peptide-1 Receptor Agonists on Atrial Fibrillation Recurrence After Catheter Ablation
JACC: Clinical Electrophysiology · 2024-08 · 10 (8) · 1848-1855
DOI: 10.1016/j.jacep.2024.03.031 ↗Kurz gefasst
Fachartikel in der Zeitschrift JACC: Clinical Electrophysiology, 2024-08. Verfasst von Danish Iltaf Satti und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Atrial Fibrillation, Catheter Ablation, Recurrence, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Relationship between glucagon-like peptide-1 receptor agonist (GLP-1 RA) use prior to atrial fibrillation (AF) ablation and subsequent AF recurrence is not well-understood. OBJECTIVES: This study investigated the effects of GLP-1 RA use within 1 year before ablation and its association with AF recurrence and associated outcomes. METHODS: The TriNetX research database was used to identify patients aged ≥18 years undergoing AF ablation (2014-2023). Patients were categorized into 2 groups, and propensity score matching (1:1) between preablation GLP-1 RA users and nonusers was performed based on demographics, comorbidities, body mass index, laboratory tests, AF subtype, and medications. Primary outcome was composite of cardioversion, new antiarrhythmic drug therapy, or repeat AF ablation after a 3-month blanking period following the index ablation. Additional outcomes included ischemic stroke, all-cause hospitalization, and mortality during 12-month follow-up period. RESULTS: After 1:1 propensity score matching, the study cohort comprised 1,625 GLP-1 RA users and 1,625 matched GLP-1 RA nonusers. Preablation GLP-1 RA therapy was not associated with a lower risk of cardioversion, new AAD therapy, and repeat AF ablation after the index procedure (HR: 1.04 [95% CI: 0.92-1.19]; log-rank P = 0.51). Furthermore, the risk of ischemic stroke, all-cause hospitalization, and mortality during the 12-month follow-up period did not differ between the 2 groups. CONCLUSIONS: These findings suggest that preprocedural use of GLP-1 RAs is not associated with a reduced risk of AF recurrence or associated adverse outcomes following ablation, and underscore the need for future research to determine whether these agents improve outcome in AF patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Cardiovascular Analytics Group, Hong Kong-China-UK Collaboration, Hong Kong.
- Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Electronic address: dspragg1@jhmi.edu.
Zitieren
APA
Satti, D. I., Karius, A., Chan, J. S. K., Isakadze, N., Yadav, R., Garg, K., Aronis, K. N., Marine, J. E., Berger, R., Calkins, H., & Spragg, D. (2024). Effects of Glucagon-Like Peptide-1 Receptor Agonists on Atrial Fibrillation Recurrence After Catheter Ablation. JACC: Clinical Electrophysiology, 10(8), 1848-1855. https://doi.org/10.1016/j.jacep.2024.03.031
Vancouver
Satti DI, Karius A, Chan JSK, Isakadze N, Yadav R, Garg K, et al. Effects of Glucagon-Like Peptide-1 Receptor Agonists on Atrial Fibrillation Recurrence After Catheter Ablation. JACC: Clinical Electrophysiology. 2024;10(8):1848-1855. doi:10.1016/j.jacep.2024.03.031
BibTeX
@article{Satti2024,
author = {Satti, Danish Iltaf and Karius, Alexander and Chan, Jeffrey Shi Kai and Isakadze, Nino and Yadav, Ritu and Garg, Keva and Aronis, Konstantinos N and Marine, Joseph E and Berger, Ronald and Calkins, Hugh and Spragg, David},
title = {Effects of Glucagon-Like Peptide-1 Receptor Agonists on Atrial Fibrillation Recurrence After Catheter Ablation},
journal = {JACC: Clinical Electrophysiology},
year = {2024},
volume = {10},
number = {8},
pages = {1848--1855},
doi = {10.1016/j.jacep.2024.03.031}
}
EUVIMED